scispace - formally typeset
Search or ask a question
Institution

Eli Lilly and Company

CompanyIndianapolis, Indiana, United States
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Agonist. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Agonist, Insulin, Placebo, Olanzapine


Papers
More filters
Journal ArticleDOI
TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Abstract: Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. Methods We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15. Results A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P = 0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, -5.0 percentage points; 95% CI, -9.8 to -0.3; P = 0.03), as were new infections (5.9% vs. 11.2%; difference, -5.3 percentage points; 95% CI, -8.7 to -1.9; P = 0.003). Conclusions Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.).

1,301 citations

Journal ArticleDOI
TL;DR: It is shown here that fibroblast growth factor 21 (FGF21) plays a physiologic role in this thermogenic recruitment of WATs and acts to activate and expand the thermogenic machinery in vivo to provide a robust defense against hypothermia.
Abstract: Certain white adipose tissue (WAT) depots are readily able to convert to a "brown-like" state with prolonged cold exposure or exposure to β-adrenergic compounds. This process is characterized by the appearance of pockets of uncoupling protein 1 (UCP1)-positive, multilocular adipocytes and serves to increase the thermogenic capacity of the organism. We show here that fibroblast growth factor 21 (FGF21) plays a physiologic role in this thermogenic recruitment of WATs. In fact, mice deficient in FGF21 display an impaired ability to adapt to chronic cold exposure, with diminished browning of WAT. Adipose-derived FGF21 acts in an autocrine/paracrine manner to increase expression of UCP1 and other thermogenic genes in fat tissues. FGF21 regulates this process, at least in part, by enhancing adipose tissue PGC-1α protein levels independently of mRNA expression. We conclude that FGF21 acts to activate and expand the thermogenic machinery in vivo to provide a robust defense against hypothermia.

1,263 citations

Journal ArticleDOI
Antonio F. Pardiñas1, Peter Holmans1, Andrew Pocklington1, Valentina Escott-Price1, Stephan Ripke2, Stephan Ripke3, Noa Carrera1, Sophie E. Legge1, Sophie Bishop1, D. F. Cameron1, Marian L. Hamshere1, Jun Han1, Leon Hubbard1, Amy Lynham1, Kiran Kumar Mantripragada1, Elliott Rees1, James H. MacCabe4, Steven A. McCarroll5, Bernhard T. Baune6, Gerome Breen4, Gerome Breen7, Enda M. Byrne8, Udo Dannlowski9, Thalia C. Eley4, Caroline Hayward10, Nicholas G. Martin11, Nicholas G. Martin8, Andrew M. McIntosh10, Robert Plomin4, David J. Porteous10, Naomi R. Wray8, Armando Caballero12, Daniel H. Geschwind13, Laura M. Huckins14, Douglas M. Ruderfer14, Enrique Santiago15, Pamela Sklar14, Eli A. Stahl14, Hyejung Won13, Esben Agerbo16, Esben Agerbo17, Thomas Damm Als17, Thomas Damm Als16, Ole A. Andreassen18, Ole A. Andreassen19, Marie Bækvad-Hansen16, Marie Bækvad-Hansen20, Preben Bo Mortensen16, Preben Bo Mortensen17, Carsten Bøcker Pedersen16, Carsten Bøcker Pedersen17, Anders D. Børglum17, Anders D. Børglum16, Jonas Bybjerg-Grauholm16, Jonas Bybjerg-Grauholm20, Srdjan Djurovic18, Srdjan Djurovic21, Naser Durmishi, Marianne Giørtz Pedersen16, Marianne Giørtz Pedersen17, Vera Golimbet, Jakob Grove, David M. Hougaard20, David M. Hougaard16, Manuel Mattheisen17, Manuel Mattheisen16, Espen Molden, Ole Mors16, Ole Mors22, Merete Nordentoft16, Merete Nordentoft23, Milica Pejovic-Milovancevic24, Engilbert Sigurdsson, Teimuraz Silagadze25, Christine Søholm Hansen16, Christine Søholm Hansen20, Kari Stefansson26, Hreinn Stefansson26, Stacy Steinberg26, Sarah Tosato27, Thomas Werge16, Thomas Werge28, Thomas Werge23, David A. Collier29, David A. Collier4, Dan Rujescu30, Dan Rujescu31, George Kirov1, Michael J. Owen1, Michael Conlon O'Donovan1, James T.R. Walters1 
TL;DR: A new genome-wide association study of schizophrenia is reported, and through meta-analysis with existing data and integrating genomic fine-mapping with brain expression and chromosome conformation data, 50 novel associated loci and 145 loci are identified.
Abstract: Schizophrenia is a debilitating psychiatric condition often associated with poor quality of life and decreased life expectancy. Lack of progress in improving treatment outcomes has been attributed to limited knowledge of the underlying biology, although large-scale genomic studies have begun to provide insights. We report a new genome-wide association study of schizophrenia (11,260 cases and 24,542 controls), and through meta-analysis with existing data we identify 50 novel associated loci and 145 loci in total. Through integrating genomic fine-mapping with brain expression and chromosome conformation data, we identify candidate causal genes within 33 loci. We also show for the first time that the common variant association signal is highly enriched among genes that are under strong selective pressures. These findings provide new insights into the biology and genetic architecture of schizophrenia, highlight the importance of mutation-intolerant genes and suggest a mechanism by which common risk variants persist in the population.

1,259 citations

Journal ArticleDOI
TL;DR: Improved the docking accuracy did not necessarily enhance the ability to estimate binding affinities using the docked structures, and statistical analysis shows that even lower‐accuracy grid‐based energy representations can be effectively used when followed with full force field minimization.
Abstract: The influence of various factors on the accuracy of protein-ligand docking is examined. The factors investigated include the role of a grid representation of protein-ligand interactions, the initial ligand conformation and orientation, the sampling rate of the energy hyper-surface, and the final minimization. A representative docking method is used to study these factors, namely, CDOCKER, a molecular dynamics (MD) simulated-annealing-based algorithm. A major emphasis in these studies is to compare the relative performance and accuracy of various grid-based approximations to explicit all-atom force field calculations. In these docking studies, the protein is kept rigid while the ligands are treated as fully flexible and a final minimization step is used to refine the docked poses. A docking success rate of 74% is observed when an explicit all-atom representation of the protein (full force field) is used, while a lower accuracy of 66-76% is observed for grid-based methods. All docking experiments considered a 41-member protein-ligand validation set. A significant improvement in accuracy (76 vs. 66%) for the grid-based docking is achieved if the explicit all-atom force field is used in a final minimization step to refine the docking poses. Statistical analysis shows that even lower-accuracy grid-based energy representations can be effectively used when followed with full force field minimization. The results of these grid-based protocols are statistically indistinguishable from the detailed atomic dockings and provide up to a sixfold reduction in computation time. For the test case examined here, improving the docking accuracy did not necessarily enhance the ability to estimate binding affinities using the docked structures.

1,241 citations

Journal ArticleDOI
04 Jul 2007-Nature
TL;DR: The identification of a somatic mutation in human breast, colorectal and ovarian cancers that results in a glutamic acid to lysine substitution at amino acid 17 (E17K) in the lipid-binding pocket of AKT1 is reported.
Abstract: A recurrent mutation found in the akt1 gene has been identified in breast, ovarian and colorectal tumours The crystal structure of the mutant protein is determined and it is found that the protein displays in increased plasma membrane localization and functions as an oncogene in vitro and in a mouse model for leukaemia

1,203 citations


Authors

Showing all 17866 results

NameH-indexPapersCitations
Mark J. Daly204763304452
Irving L. Weissman2011141172504
Eric J. Topol1931373151025
Tony Hunter175593124726
Xiang Zhang1541733117576
Jerrold M. Olefsky14359577356
Stephen F. Badylak13353057083
George A. Bray131896100975
Lloyd Paul Aiello13150685550
Levi A. Garraway12936699989
Mark Sullivan12680263916
James A. Russell124102487929
Tony L. Yaksh12380660898
Elisabetta Dejana12243048254
Hagop S. Akiskal11856550869
Network Information
Related Institutions (5)
Pfizer
37.4K papers, 1.6M citations

98% related

Merck & Co.
48K papers, 1.9M citations

97% related

Novartis
50.5K papers, 1.9M citations

97% related

Hoffmann-La Roche
43K papers, 1.6M citations

93% related

National Institutes of Health
297.8K papers, 21.3M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20236
202287
2021815
2020868
2019732
2018742